We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

22 hedge funds and large institutions have $33.9M invested in Estrella Immunopharma in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more funds holding

Funds holding: 21 → 22 (+1)

3% more capital invested

Capital invested by funds: $32.9M → $33.9M (+$1.02M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11.49% less ownership

Funds ownership: 69.44% → 57.95% (-11%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CSS
Cubist Systematic Strategies
Connecticut
+$2.18M
2
OFG
OTA Financial Group
New York
+$56.6K

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$1.24M
2
KIM
Karpus Investment Management
New York
-$1K

ESLA Hedge Fund Activity: Q2 2022 in Review

22 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q2 2022, worth a combined $33.9M — up 3.1% from $32.9M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ESLA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Cubist Systematic Strategies, opening a new position worth an estimated $2.18M. The largest seller was Linden Advisors, cutting an estimated $1.24M.

  • 22 institutional investors held Estrella Immunopharma (ESLA) as of Q2 2022, up from 21 in Q1 2022.
  • Funds reported $33.9M of Estrella Immunopharma stock for Q2 2022, up 3.1% quarter-over-quarter.
  • 1 fund opened new Estrella Immunopharma positions in Q2 2022 and 0 closed out, a net change of +1 holder.
  • The largest Estrella Immunopharma buyer in Q2 2022 was Cubist Systematic Strategies, an estimated $2.18M added.
  • The largest Estrella Immunopharma seller in Q2 2022 was Linden Advisors, an estimated $1.24M sold.

Based on aggregated 13F filings for Q2 2022.